We’re taking the final two weeks of the year off for MedHeads, MedCityNews.com’s weekly video podcast looking at the business of innovation in healthcare. Instead, we’ll take the final two weeks to look at the best of Year 1 of our broadcast.
So enjoy a replay of our best MedHeads of the year: our interview with Martin Shkreli in the midst of his first controversy over the dramatic increase of Daraprim.
FierceBiotech Editor John Carroll, Timmerman Report founder Luke Timmerman and MedCity News’ biotech-pharma reporter Meghana Keshavan joined me in a discussion with Shkreli, who apologized for nothing, ripped the traditional industry leaders as hypocrites, and dodged any specifics (at the time) of lower prices and what would come next.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.
I re-watched it and was amazed at – as outrageous as we thought he was then – how much further he went after this.
Photo: Big Stock Photos